SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The revenue for the September 2025 quarter is pegged at Rs. 10226.50 millions, about 7.00% up against Rs. 9557.60 millions recorded during the year-ago period.Net profit stood at Rs. 2004.20  millions  compared to Rs. 1731.20 millions in the corresponding previous quarter,high by 15.77%.Operating profit for the quarter ended September 2025 rose to 3126.10 millions as compared to 2770.70 millions of corresponding quarter ended September 2024.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202509 202409 % Var 202509 202409 % Var 202503 202403 % Var
Sales 10226.50 9557.60 7.00 20625.50 19080.70 8.10 37229.20 32986.40 12.86
Other Income 142.50 88.90 60.29 281.50 140.50 100.36 347.40 346.80 0.17
PBIDT 3126.10 2770.70 12.83 6196.30 5556.10 11.52 10526.80 9141.00 15.16
Interest 10.10 20.20 -50.00 16.70 63.40 -73.66 91.20 405.20 -77.49
PBDT 3116.00 2750.50 13.29 6179.60 5492.70 12.51 10435.60 8735.80 19.46
Depreciation 431.10 408.50 5.53 845.10 808.60 4.51 1664.50 1352.40 23.08
PBT 2684.90 2342.00 14.64 5334.50 4684.10 13.89 8771.10 7383.40 18.79
TAX 680.70 610.80 11.44 1351.60 1220.60 10.73 2245.70 1949.80 15.18
Deferred Tax 30.80 90.40 -65.93 69.80 174.10 -59.91 328.80 494.90 -33.56
PAT 2004.20 1731.20 15.77 3982.90 3463.50 15.00 6525.40 5433.60 20.09
Equity 156.60 155.30 0.84 156.60 155.30 0.84 155.70 155.20 0.32
PBIDTM(%) 30.57 28.99 5.45 30.04 29.12 3.17 28.28 27.71 2.04

JB Chem & Pharma Share Price

1998.65 -5.10 (-0.25%)
13-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1652.00
Dr. Reddys Lab 1235.20
Cipla 1211.30
Zydus Lifesciences 923.10
Lupin 2312.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×